Trulicity Dulaglutide

Trulicity Dulaglutide

Facts of Trulicity Dulaglutide?

  • Medicine Name: TRULICITY
  • Generic Name: Dapagliflozin
  • Approval Date: Sept. 18, 2014
  • Company Name: Eli Lilly and Company
  • Available as (Form & Strength): Injection: 0.75 mg/0.5 mL solution in a single – dose pen, Injection: 1.5 mg/0.5 mL solution in a single – dose pen, Injection: 0.75 mg/0.5 mL solution in a single – dose prefilled syringe, Injection: 1.5 mg/0.5 mL solution in a single – dose prefilled syringe

What is indication and usage?

  • TRULICITY ™ is a glucagon – like peptide (GLP – 1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .

Limitation of Use

  • TRULICITY is not recommended as a first – line therapy for patients who h av e inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C – cell tumor findings to humans . Prescribe TRULICITY only to patients for whom the potential ben efits outweigh the potential risk
  • TRULICITY has not been studied in patients with a history of pancreatitis
  • TRULICITY should not be used in patients w ith type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. TRULICITY is not a substitute for insulin.
  • TRULICITY has not been studied in patients wit h sev ere gastrointestinal disease, including sev ere gastroparesis. The use of TRULICITY is not recommended in patients with pre – ex isting sev ere gastrointestinal disease
  • The concurrent use of TRULICITY and basal insulin has not been studied

What is FARXIGA?

Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Trulicity is not recommended as first-line therapy for patients inadequately controlled on diet and exercise. It has not been studied in patients with a history of pancreatitis, and other antidiabetic therapies should be considered for patients with a history of pancreatitis. Trulicity is not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Trulicity is not a substitute for insulin and has not been studied in combination with basal insulin. Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is not for patients with pre-existing severe gastrointestinal disease.